ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GE-287

A development code.

Its studies are mostly in Cognitive Dysfunction, led by GE Healthcare.

Furthest: phase 2, since Sep 21, 20261 company-led study, 1 open or runningNext primary completion: Feb 25, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GE Healthcare11 open or runningphase 2since Sep 21, 2026Sep 21, 2026Feb 25, 2027phase 2 · NCT07873463

Also a collaborator on its studies: PSI CRO.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 21, 2026First study: phase 2 study in Cognitive DysfunctionFirst studyNCT07873463 · 20 planned · United States

Ahead

  1. Feb 25, 2027Primary completion: phase 2 study in Cognitive DysfunctionNCT07873463

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07873463Cognitive Dysfunction · United States2RecruitingFeb 25, 202720

How it is read

Names in the registry

  • “GE-287”, 2 entries

Codes read as this program: GE287.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.